Show simple item record

dc.contributor.authorMasyuko, Sarah J.
dc.contributor.authorPage, Stephanie T.
dc.contributor.authorKinuthia, John
dc.contributor.authorOsoti, Alfred O.
dc.contributor.authorPolyak, Stephen J.
dc.contributor.authorOtieno, Fredrick C.
dc.contributor.authorKibachio, Joseph M.
dc.contributor.authorMogaka, Jerusha N
dc.contributor.authorTemu, Tecla M.
dc.contributor.authorZifodya, Jerry S.
dc.contributor.authorOtedo, Amos
dc.contributor.authorNakanjako, Damalie
dc.contributor.authorHughes, James P.
dc.contributor.authorFarquhar, Carey
dc.date.accessioned2025-07-02T11:54:48Z
dc.date.available2025-07-02T11:54:48Z
dc.date.issued2020
dc.identifier.citationMasyuko, S.J. et al. (2020). Metabolic syndrome and 10-year cardiovascular risk among HIV-positive and HIV-negative adults: A cross-sectional study. Medicine, 99(27): e20845.en_US
dc.identifier.uri10.1097/MD.0000000000020845
dc.identifier.urihttp://hdl.handle.net/10570/14611
dc.description.abstractTo determine the prevalence and correlates of metabolic syndrome (MetS) and compare 10-year cardiovascular disease (CVD) risk among Kenyan adults with and without HIV infection.We conducted a cross-sectional study among adults ≥30 years of age with and without HIV infection seeking care at Kisumu County Hospital. Participants completed a health questionnaire and vital signs, anthropomorphic measurements, and fasting blood were obtained. MetS was defined using 2009 Consensus Criteria and 10-year Atherosclerotic CVD (ASCVD) risk score was calculated. Chi-square, independent t tests, Wilcoxon ranksum test and multivariable logistic regression were used to determine differences and associations between HIV and MetS, CVD risk factors and ASCVD risk score.A total of 300 people living with HIV (PLWHIV) and 298 HIV-negative participants with median age 44 years enrolled, 50% of whom were female. The prevalence of MetS was 8.9% overall, but lower among PLWHIV than HIV-negative participants (6.3% vs 11.6%, respectively; P = .001). The most prevalent MetS components were elevated blood pressure, decreased high density lipoprotein, and abdominal obesity. Adjusting for covariates, PLWHIV were 66% less likely to have MetS compared to HIV-negative participants (adjusted odds ratio [aOR] 0.34; 95% confidence interval [95%CI] 0.18, 0.65; P = .005). Median ASCVD risk score was also lower among PLWHIV compared to HIV-negative participants (1.7% vs 3.0%, P = .002).MetS was more common among HIV-negative than HIV-positive adults, and HIV-negative adults were at greater risk for CVD compared to PLWHIV. These data support integration of routine CVD screening and management into health programs in resource-limited settings, regardless of HIV status.en_US
dc.description.sponsorshipNational Institutes of Health (NIH) R21TW010459, Fogarty International Center (FIC) D43 TW009580.en_US
dc.language.isoenen_US
dc.publisherWolters Kluweren_US
dc.subjectMetabolic syndromeen_US
dc.subjectCardiovascular risken_US
dc.subjectHuman Immunodeficiency Virusen_US
dc.subjectKenyaen_US
dc.subjectPLWHIVen_US
dc.subjectHIV/AIDSen_US
dc.subjectCardiovascular diseaseen_US
dc.titleMetabolic syndrome and 10-year cardiovascular risk among HIV-positive and HIV-negative adults: A cross-sectional studyen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record